title: Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients.
abstract: Cancer patients suffer from vaginal dryness and dyspareunia earlier and longer than the general population, with more severe and distressing symptoms. Life-style advices are the first step and vaginal lubricants can be tried, but they can't completely relieve atrophic symptoms. The most effective therapy is use of vaginal estrogens, but compliance and management are particularly difficult in estrogen sensitive cancer patients because of their systemic absorption. Compliance can be improved if they are begun at a very low dose and gradually increased until the lowest effective dose is reached. Promestriene only possesses an intramucosal effect, it can be used at very low doses in cancer patients suffering from urogenital symptoms.
authors.affiliation: Gynecological Oncology, National Cancer Institute, Aviano, PN, Italy. ldelpup@cro.it
authors.forename: Lino
authors.initials: L
authors.lastname: Del Pup
mesh_terms: D000282:Administration, Intravaginal; D004414:Dyspareunia / Q000188:drug therapy* / Q000209:etiology; D004967:Estrogens / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D054327:Lubricants; D008153:Lubrication; D009369:Neoplasms / Q000150:complications*; D014621:Vagina / Q000187:drug effects*; D014623:Vaginal Diseases / Q000188:drug therapy* / Q000209:etiology
chemical_list: D004967:Estrogens; D054327:Lubricants